Immunovant, Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
IMVT$35.15+15.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 2.1+ | Share Exchange Agreement, dated September 29, 2019, by and among Immunovant Sciences Ltd., the stockholders of Immunovant Sciences Ltd., Roivant Sciences Ltd., and Health Sciences Acquisitions Corporation. | 8-K | 001-38906 | 2.1 | October 2, 2019 |
| 3.1 | Amended and Restated Certificate of Incorporation of Immunovant, Inc. | 8-K | 001-38906 | 3.1 | December 20, 2019 |
| 3.2 | Amended and Restated Bylaws of Immunovant, Inc. | 8-K | 001-38906 | 3.2 | December 20, 2019 |
| 10.1† | Employment Agreement with Tiago Girao, dated as of April 21, 2025. | 10-K | 001-38906 | 10.19 | May 29, 2025 |
| 10.2†* | Separation Agreement and General Release with Renee Barnett, dated as of May 9, 2025. | ||||
| 10.3† | Separation Agreement and General Release with Peter Salzmann, dated as of May 30, 2025. | 10-K | 001-38906 | 10.25 | May 29, 2025 |
| 10.4†* | Employment Agreement with Eric Venker, dated as of July 28, 2025. | ||||
| 10.5†* | Form of Capped Value Appreciation Right Award Grant Notice and Award Agreement under 2019 Equity Incentive Plan of Immunovant, Inc. | ||||
| 10.6† | Roivant Sciences Ltd. 2021 Equity Incentive Plan | S-8 | 333-260173 | 99.1 | October 8, 2021 |
| 31.1* | Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 31.2* | Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 32.1# | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||
| 32.2# | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||
| 101.INS* | Inline XBRL Instance Document | ||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents | ||||
| 104* | Cover Page Interactive Data (embedded within the Inline XBRL document) | ||||
- Filed herewith.
- The annexes, schedules, and certain exhibits to the Share Exchange Agreement have been omitted pursuant to
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.